EP1539063B2

A delivery system and a manufacturing process of a delivery system

Abstract

This record has no abstract on file.

EP1539063B2, drawing sheet 1
Sheet 1 of 7

Term

Term ended

Expired 4 September 2023, 3.1 years ago.

  1. Priority
  2. Filed
  3. Granted
  4. Expired
  5. Today

8 claims: 5 independent, 3 dependent

  1. 1
    A manufacturing process of a delivery system, said system comprising a body construction and at least one capsule containing a pharmaceutical composition, said capsule having at least a first end and a second end, characterized in that said body construction, having at least two locking parts, each locking part having at least a first end and a second end, said first end of each locking part having a surface adapted to face and cover one of the at least first and second ends of the capsule, the diameter of at least one of the locking parts varying along its length between said first end and said second end, is injection moulded and in that said capsule is injection moulded on the body construction, between said at least two locking parts, in a further step, and in that said locking parts (9, 10) have the shape of a truncated cone and in that the end of the truncated cone having a larger diameter is the end having the said surface facing said end of the capsule (8).
  2. 2
    The process according to Claim 1, characterized in that said body construction consists of one body part.
  3. 5
    The process according to any of the preceding claims, characterized in that the surface of the cross-section of said at least first or second end of the capsule (8) is essentially smaller than said surface of the locking part (9, 10) facing said end.
  4. 6
    The process according to any of the preceding claims, characterized in that it has two or more capsules (8) containing a pharmaceutical composition.
  5. 7
    The process according to any of the preceding claims, characterized in that said capsule (8) containing a pharmaceutical composition consists essentially of a biocompatible polymer and at least one pharmaceutically active agent.
  6. 8
    The process according to any of the preceding claim, characterized in that said system is an intrauterine system.